Merck, EyeBio announce initiation of Phase 2b/3 clinical trial for Restoret for Diabetic Macular Edema Ruchika Sharma8 Sept 2024 4:00 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., Inc., Rahway,...
Lupin completes Phase 3 trials for Lucentis biosimilar Ruchika Sharma6 Aug 2024 4:30 PM ISTMumbai: Global Pharma major Lupin Limited has announced the successful completion of a global Phase 3 clinical study of LUBT010, its biosimilar...
New eye drops found safe and effective in diabetic retinopathy and diabetic macular edema in New trial Dr. Kamal Kant Kohli14 March 2024 1:15 AM ISTNew eye drop treatment has been found to be safe and tolerable with 100% participants completing the study for diabetic retinopathy and diabetic...
Roche Pharma India forays into Ophthalmology space with launch of Vabysmo Ruchika Sharma6 March 2024 4:10 PM ISTAs the world's first bispecific antibody, Vabysmo is a single molecule designed to target and inhibit the effects of two targets, providing the...
Conbercept efficacious in short-term treatment of Diabetic Macular Edema with or without Diabetic Nephropathy Dr Riya Dave20 Feb 2024 2:45 PM ISTDiabetic macular edema (DME) is a common complication of diabetes, and when coupled with diabetic nephropathy (DN), it poses additional challenges to...
Bayer Eylea 8 mg gets Japanese marketing nod Ruchika Sharma21 Jan 2024 1:00 PM ISTBerlin: Bayer has announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted market authorization for Eylea 8 mg...
Sun Pharma Gets CDSCO Panel Nod for Additional Indication of Ranibizumab solution for injection Dr. Divya Colin16 Jan 2024 6:00 PM ISTNew Delhi: In line with the proposal presented by the drug major Sun Pharma, the Subject Expert Committee (SEC) functional under the Central Drug...
Bayer Eylea 8 mg approved in EU for treatment of two major retinal diseases Ruchika Sharma11 Jan 2024 3:30 PM ISTBerlin: Bayer has announced that the European Commission has granted marketing authorization in the European Union (EU) for new Eylea 8 mg...
Faricimab outperforms anti-VEGF Drugs in DME and AMD Treatment by improving central subfoveal thickness Aditi5 Jan 2024 10:45 PM ISTIn the industrialized world, Neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) cause blindness. Faricimab, launched...
Brolucizumab Shows Promising Outcomes for Diabetic Macular Edema Care Jacinthlyn Sylvia3 Dec 2023 6:00 PM ISTAn update of a 52-week clinical trial unveiled promising results of brolucizumab compared to the standard aflibercept in enhancing diabetic macular...
Brolucizumab as good as aflibercept for improving clinical outcomes in Diabetic Macular Edema Outcomes: JAMA Jacinthlyn Sylvia19 Nov 2023 5:00 PM ISTA recent 52-week phase 3 clinical trial published in the Journal of American Medical Association compared the efficacy and safety of brolucizumab...
Bayer Aflibercept 8 mg recommended for approval in EU Ruchika Sharma15 Nov 2023 1:00 PM ISTBerlin: Bayer has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a...
